



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



REQUEST FOR QUOTATION no. 5/2025/G/LNP dated 06.05.2025

Application No. FENG.01.01-IP.01-A00Y/24

In connection with the planned implementation of the project entitled "Development of an mRNA complex with lipid nanoparticles (LNP) with reduced immunogenicity for use in protein replacement therapy" under the European Funds for Smart Economy Programme, Recruitment FENG.01.01-IP.01-001/24, Measure FENG.01.01 SMART Path, Priority FENG.01 Support for entrepreneurs.

CONTRACTING AUTHORITY:

Celon Pharma S.A.

2A Ogrodowa Street,

05-092 Kielpin

VAT no.: 118-16-42-061

PARTIAL BIDS ACCEPTED: NO

ACCEPTANCE OF VARIANT OFFERS: NO

ORDER COMPLETION DATE: no later than by 31 July 2025

I. ORDERING PROCEDURE:

- This order is not subject to the provisions of the Act of 11 September 2019. *Public Procurement Law*;
- This procurement is carried out in accordance with the principles of competitiveness, openness, transparency and equal access;
- The Contracting Authority reserves the right to cancel the procedure at any stage, without giving reasons;
- The Contracting Authority shall inform the Bidders and publish relevant information on the website of the Competitiveness Database in the event of changes to this request for proposal;
- The Contracting Authority reserves the right to ask the Bidders supplementary questions regarding additional information, documents or explanations;

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, Research and Development Centre: 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: PLN 5,385,650, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



- In justified cases, before the deadline for submission of tenders, the Contracting Authority reserves the right to modify or amend the content of the invitation to submit tenders;
- This invitation to submit tenders does not oblige the Contracting Authority to conclude a contract.

II. DESCRIPTION OF THE SUBJECT OF THE REQUEST FOR QUOTATION

CPV code: 33696500-0

Set 1.

No.	Description	Package size	Quantity
1.	3-Maleimidopropionic acid, 98%, CAS: 7423-55-4 (Angene product no. AG0033QM or equivalent)	50 g	1
2.	6-Maleimidoheptanoic acid, 98%, CAS: 55750-53-3 (Angene product no. AG00I9Y1 or equivalent)	50 g	1
3.	Methyltetrazine acid, 98%, CAS: 1380500-88-8 (Angene product no. AG00HV81 or equivalent)	1 g	1
4.	1-Propanamine, 3-[4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenoxy]-, hydrochloride (1:1), 98%, CAS: 1802908-03-7 (Angene product no. AG01RO4J or equivalent)	1 g	1
5.	(4-(6-Methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanamine hydrochloride, 97%, CAS: 1596117-29-1 (Angene product no. AG01EGB6 or equivalent)	5 g	1
6.	(E)-Cyclooct-4-enol, 95%, CAS: 85081-69-2 (Angene product no. AG00GAB4 or equivalent)	1 g	1
7.	(S)-11-Benzyl-1-(9H-fluoren-9-yl)-3,6,9,12,15-pentaoxo-2,18-dioxa-4,7,10,13,16-pentaazaicosan-20-oic acid, 95%, CAS: 2264011-98-3 (Angene product no. AG020MCR or equivalent)	2 g	1

Due to the continuation of research work as part of the project in question, its specificity and unique nature, the reagents/materials used in the research process will significantly influence the shape of the R&D work conducted; for objective technical reasons, the catalogue number of the product/s was provided in the description of the subject of the order.

III. TERMS AND CONDITIONS OF PARTICIPATION IN THE REQUEST FOR QUOTATION

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: PLN 5,385,650, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



1. Due to the unique nature, unrepeatable nature, strictly defined methodology of the conducted projects, scientific research and experiments as well as the need to maintain continuity and repeatability of the research conducted by the Ordering Party, the Bidder offering products equivalent to the products described in this request for proposals is obliged to:
 - demonstration based on technical documentation/reagent safety data sheets/etc. and a written declaration that the equivalent products offered by him meet the requirements allowing the continuation of the Ordering Party's scientific research without the need to perform additional activities (procedures), including e.g. calibration of devices, validation of developed laboratory methods;
 - demonstrate (through a written declaration in the submitted offer) that the offered equivalent products will not result in increased costs due to the need to purchase additional products and other consumables;
 - accept responsibility – in the form of a written declaration – for damage to the equipment resulting from the use of the offered and delivered equivalent products, based on the opinion issued by an authorized service center of the equipment manufacturer;
 - Together with the offer, a "Declaration on the absence or lack of influence of personal or capital links with the Ordering Party on the impartiality of the proceedings" should also be submitted, which is Att. 1 to this request for quotation.

IV. CRITERIA FOR THE SELECTION OF TENDERS

Price (P) – 100 points (100%)

Method of assessment:

Criterion	Weight (%)	Maximum number of points to be obtained	Method of evaluation according to the following formula
Price	100%	100 pts	<p>Price "P" – 100 points (this is 100% of the maximum number of points to gain)</p> $\frac{Price_{lowest}}{Price_{service}} \times 100 \text{ points}$ <p>Where:</p> <p>Price_{lowest} – the lowest price among quotes.</p> <p>Price_{service} – price for the given tenderer.</p>

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: **PLN 5,385,650**, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



The total number of points that a given offer will receive will be calculated according to the following formula:

$$L = P$$

L – total number of points;

P – points obtained in the "Price" criterion.

V. ADDRESS AND DEADLINE FOR SUBMISSION OF TENDERS

1. The offer should be submitted via the website of the Competitiveness Database

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/>;

Below is instruction how to add an offer:

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/pomoc/59-help-for-abroad-users-registration-pomoc-dla-uzytkownikow-zagranicznych-wersja-angielska>

<https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/pomoc/60-help-for-abroad-users-offers-pomoc-dla-uzytkownikow-zagranicznych-wersja-angielska>

2. Withdrawal from the communication referred to in point 1 is permissible if:
 - a) the nature of the order requires the use of tools, devices or file formats that are not supported with BK2021, or
 - b) file format applications that are suitable for the preparation of bids or competition entries, use file formats that cannot be supported by any other open source or generally available applications, or are licensed and cannot be made available for download or remote use by the Contracting Authority, or
 - c) the procurer requires the submission of a physical model, scale model or sample that cannot be provided via BK2021, or
 - d) this is necessary due to the need to protect sensitive information, which cannot be sufficiently guaranteed by BK2021.

In such cases, the offer with the required attachments should be submitted to the e-mail address paulina.gruszka@celonpharma.com.

3. The offer must be submitted no later than **13.05.2025.**;
4. Offers submitted after the deadline indicated above will not be considered;
5. Offers will be evaluated no later than **30.05.2025.**;

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: **PLN 5,385,650**, KRS: 0000437778, **NIP:** 1181642061, **BDO:** 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



6. Offers submitted in foreign currency will be converted according to the exchange rate of the National Bank of Poland on the date of resolution of the request for quotation.
7. Information on the selection of offers will be published on the website of the <https://bazakonkurencyjnosci.funduszeuropejskie.gov.pl/> Competitiveness Database.

VI. PROHIBITION OF CONFLICTS OF INTEREST

A conflict of interest is unacceptable, therefore the Bidder is obliged to sign a statement (Att. 1) on the lack of existence or lack of impact of personal or capital relations with the Purchaser on the impartiality of the proceedings consisting of:

- a) participating in a company as a partner in a civil law partnership or partnership, holding at least 10% of shares or stocks (unless a lower threshold results from the provisions of law), performing the function of a member of the supervisory or management body, proxy;
- b) being married, in a relationship of kinship or affinity in the direct line, kinship or affinity in the collateral line up to the second degree, or in a relationship due to adoption, care or guardianship or being in cohabitation with the Purchaser, its legal representative or members of the management or supervisory bodies of contractors applying for the award of the contract;
- c) remaining in such a legal or factual relationship with the Purchaser that there is a justified doubt as to their impartiality or independence in connection with the procurement procedure.

A conflict of interest means any situation in which persons involved in the preparation or conduct of a procurement procedure or who may influence the outcome of that procedure have, directly or indirectly, a financial, economic or other personal interest which may be perceived as threatening their impartiality and independence in connection with the procurement procedure.

VII. PRESENTATION OF OFFERS

1. Each Bidder may submit only one offer in Polish or English;
2. The offer must include:
 - The number of the request for quotation
 - Date of preparation of the offer
 - The details of the Bidder: address, e-mail address, Tax Identification Number (NIP) (if available),

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: **PLN 5,385,650**, KRS: 0000437778, **NIP:** 1181642061, **BDO:** 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



- Include detailed information on the compliance of the proposed subject matter of the RfQ with the specification,
 - Order completion date,
 - If the offer was submitted by the Bidder operating in Poland: net price, gross price and tax due,
 - If the offer was submitted by the Bidder operating outside Poland: net price and information on the absence of VAT and other taxes.
3. **The offer must remain valid for at least 30 days;**
 4. The costs of preparing the offer shall be borne by the Tenderer;
 5. **The due date of each invoice must be at least 30 days;**
 6. **The offer must be signed by persons authorised to represent the Contractor/Supplier (according to the National Court Register or power of attorney).**

VIII. CONCLUSION OF THE CONTRACT

The bidder, whose offer is assessed as the most advantageous, is obliged to conclude a contract with the Contracting Authority. If the Tenderer whose offer has been selected refuses to conclude the contract, the Contracting Authority has the right to select the next Tenderer whose offer was the most advantageous among the remaining offers.

IX. CONTRACTUAL PENALTIES

The Bidder shall pay the Ordering Party contractual penalties:

- for delay in the delivery date of the subject of the order, for each commenced day of delay, unless the delay is due to the Ordering Party's fault,
- if the results of tests conducted using an equivalent product are inconsistent with expectations,,
- the supplier agrees to deduct the amount of contractual penalties directly from the payment of the VAT invoice concerning the delivery.

Comments:

- Due to the necessity to maintain the continuity of research, the Purchaser provides for the possibility of placing a supplementary order in the amount not exceeding 50% of the contract value specified in the contract concluded with the selected Contractor/Supplier;

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: **PLN 5,385,650**, KRS: 0000437778, NIP: 1181642061, BDO: 00010958



European Funds
for Smart Economy



Republic
of Poland

Co-funded by the
European Union



- The Purchaser allows for the possibility of cancelling the order or resigning from the order of goods and services included in the partial procedure or from the entire procedure, in the event of failure to obtain funds for the performance of this contract or in other cases when the performance of the order will not be in the interest of the Contracting Authority;
- The Purchaser reserves the right to amend the contract concluded with the selected Tenderer as a result of the public procurement procedure for the following reasons:
 - a) justified changes in the manner in which the subject matter of the contract is performed,
 - b) objective reasons beyond the control of the Contracting Authority or the Tenderer,
 - c) changes in legal regulations in force on the date of signing the agreement,
 - d) Majeure
 - e) the occurrence of another obstacle beyond the control of the Tenderer, preventing the performance of the work,
 - f) in the event of introducing changes to the Subject of the Agreement exceeding the material and/or financial scope indicated in the Offer, the Parties undertake that such changes will be introduced on the basis of an appropriate annex.
- In connection with the entry into force of the Act of 13 April 2022 on Special Solutions for Counteracting Support for Aggression against Ukraine and for the Protection of National Security (Journal of Laws, item 835), entities or citizens from the Russian Federation subject to the sanctions specified in Article 1 of the above-mentioned Act are excluded from participation in this procedure, provided that they are on the list of persons and entities on the date of submission of the offer, against which sanctioning measures should be applied, maintained on the website of the Public Information Bulletin of the Minister of the Interior and Administration.

CELON PHARMA S.A.

Headquarters: 2A Ogrodowa Street, 05-092 Łomianki / Kielpin, **Research and Development Centre:** 15 Marymoncka Street, 05-152 Kazuń Nowy
Tel.: +48 22 751 59 33; e-mail: info@celonpharma.com, www.celonpharma.com

Registration authority: District Court for the Capital City of Warsaw, XIV Commercial Division of the National Court Register

President of the Management Board: Maciej Wieczorek, Share capital: **PLN 5,385,650**, KRS: 0000437778, NIP: 1181642061, BDO: 00010958